If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
142
results.
Updated on
31/08/2024 [07:25:00]
Absstract of: US2024285199A1
A continuous glucose monitoring system may utilize externally sourced information regarding the physiological state and ambient environment of its user for externally calibrating sensor glucose measurements. Externally sourced factory calibration information may be utilized, where the information is generated by comparing metrics obtained from the data used to generate the sensor's glucose sensing algorithm to similar data obtained from each batch of sensors to be used with the algorithm in the future. The output sensor glucose value of a glucose sensor may also be estimated by analytically optimizing input sensor signals to accurately correct for changes in sensitivity, run-in time, glucose current dips, and other variable sensor wear effects. Correction actors, fusion algorithms, EIS, and advanced ASICs may be used to implement the foregoing, thereby achieving the goal of improved accuracy and reliability without the need for blood-glucose calibration, and providing a calibration-free, or near calibration-free, sensor.
Absstract of: US2024285194A1
Methods and devices include automated coaching for management of glucose states by receiving a user's glucose levels using a continuous glucose monitoring (CGM) device, determining a time in range (TIR) value, determining a TIR state, receiving a glucose variability (GV) value, determining a GV state, determining a starting state based on the TIR state and the GV state, determining that the starting state corresponds to a non-ideal state, generating an optimized pathway to reach an ideal state based on one or more account vectors such as addressing self-management behavior including food, activity, and medication use. The optimized pathway may further be based on computer detection and classification of significant events of interest over time.
Absstract of: US2024285732A1
Compositions of peptide fragments of preproinsulin for the treatment of type 1 diabetes and methods for selecting one or more peptide fragments of preproinsulin suitable for subject-specific immunomodulatory therapy for type 1 diabetes. The one or more peptides may be selected based on an autoimmune phenotype for the subject, which may be characterized by a stimulation assay and/or the based on a genotype for one or more genes related to type 1 diabetes.
Absstract of: AU2024205637A1
Systems and methods are described that provide a dynamic reporting functionality that can identify important information and dynamically present a report about the important information that highlights important findings to the user. The described systems and methods are generally described in the field of diabetes management, but are applicable to other medical reports as well. In one implementation, the dynamic reports are based on available data and devices. For example, useless sections of the report, such as those with no populated data, may be removed, minimized in importance, assigned a lower priority, or the like.
Absstract of: WO2024175639A1
The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying at least one and preferably two substances to said person, - at least one and preferably two infusion sets connectable to said device; - at least one sensor for measuring a glucose concentration in the blood of said person; - a controller for controlling said device such that a certain amount of a said substance is supplied per time unit, wherein said controller is arranged to determine a slope of the measured glucose concentration and if said slope exceeds a first threshold value said controller is arranged to control the device to supply a pre-injection amount of said at least one substance, said pre-injection amount being a percentage of a maximum pre-injection amount, wherein said percentage is dependent on the determined slope.
Absstract of: WO2024175636A1
The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying at least one and preferably two substances, - at least one and preferably two infusion sets connectable to said device for infusing a said substance to said person; - at least one sensor for measuring a glucose concentration in the blood of said person; - a controller for controlling said device such that a certain amount of a said substance is supplied per time unit and thereby infused into the body of the person via said or a respective infusion set, wherein said certain amount is chosen in accordance with the measured glucose concentration, wherein said controller is arranged to determine a slope of the measured glucose concentration, and wherein the time unit per which the certain amount is supplied is dependent on said slope.
Absstract of: WO2024178261A1
A method, system, and computer readable medium for implementing the Adaptive Bio-Behavioral Control concept, which allows for bi-directional, human-machine co-regulation of metabolic disorders, such as diabetes mellitus. The Adaptive Bio-Behavioral Control concept may encompass, but is not limited thereto, three modules: a) a Physiological Adaptation Module which processes a user's historical data to estimate a personalized model of the user's glucose metabolism and to calculate suggested insulin-dosing parameters; b) a Behavioral Adaptation Module which assists the user's adaptation to the treatment action by determining a plurality of actionable information and risk assessments based on the user's glucose monitoring records; and c) a Replay Module which computes a simulation of effects from hypothetical changes to the user's treatment or behavior based on a personalized model of the user's glucose metabolism.
Absstract of: EP4420603A2
A system and method provides a glucose report for determining glycemic risk based on an ambulatory glucose profile of glucose data over a time period, a glucose control assessment based on median and variability of glucose, and indicators of high glucose variability. Time of day periods are shown at which glucose levels can be seen. A median glucose goal and a low glucose line provide coupled with glucose variability provide a view into effects that raising or lowering the median goal would have. Likelihood of low glucose, median glucose compared to goal, and variability of glucose below median provide probabilities based on glucose data. Patterns can be seen and provide guidance for treatment.
Absstract of: EP4420693A2
A method of controlling an insulin infusion device involves controlling the device to operate in an automatic basal insulin delivery mode, obtaining a blood glucose measurement for the user, and initiating a correction bolus procedure when: the measurement exceeds a correction bolus threshold value; and a maximum basal insulin infusion rate is reached during the automatic basal insulin delivery mode. The correction bolus procedure calculates an initial correction bolus amount, and scales the initial amount to obtain a final correction bolus amount, such that a predicted future blood glucose level resulting from simulated delivery of the final correction bolus amount exceeds a low blood glucose threshold level. The final amount is delivered to the user during operation in the automatic basal insulin delivery mode.
Absstract of: EP4404212A2
Continuous glucose monitoring (CGM) data and insulin delivery data are used to generate more reliable projected alarms related to a projected glucose levels. A memory stores endogenous data related to measurements of glucose level in a patient, and also stores exogenous data, such as insulin on board, both of which are used by a processor to create projected alarms. Profiles of CGM data are created for use in tuning patient-specific insulin data, such at basal rate, carb ratio, and insulin sensitivity. A processor searches for patterns in the data profiles and if found, recommended changes to patient-specific insulin data are provided to permit more accurate control over a patient's glucose levels.
Absstract of: US2024277977A1
Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
Absstract of: WO2024172352A1
Disclosed is a method for a user terminal to provide a blood glucose management service, the method including the steps of: displaying a blood glucose graph showing blood glucose information measured over time; acquiring a meal record; and displaying an exercise guideline for lowing a postprandial blood glucose spike on the basis of the meal record.
Absstract of: US2024277933A1
Equivalent insulin pump retrospective virtual basal rates for daily injections are constructed from planned insulin injections according to a virtual basal rate profile developed for a patient, and a database of historical insulin injections, i.e. basal injections actually administered by the patient, providing a unified framework for analysis, design, optimization, and adaptation of MDI (multiple daily injections) and CSII (continuous subcutaneous insulin infusion (i.e. insulin pump) treatment parameters for patients with diabetes.
Absstract of: US2024277935A1
Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, a controller module, and optionally a single point glucose monitor are provided. Integration may be manual, semi-automated and/or fully automated.
Absstract of: AU2023224252A1
The invention relates to an analyte sensor (100) for use in medical devices for measuring analyte data, in particular for measuring glucose data, comprising: a power source (102) for providing electrical power to the analyte sensor (100), an enclosure (101) of the analyte sensor, a sensor circuit (103) powered by said power source and comprising two electrodes (105, 106), wherein said electrodes (105, 106) each have a first portion (105a, 106a) that lies inside the enclosure (101) and a second portion (105b, 105b) that lies outside of the enclosure (101), at least one protection unit (107), wherein said protection unit (107) is electrically coupled to the first portion (105a, 106a) of each of the two electrodes (105, 106) that is located inside the enclosure (101), and wherein said at least one protection unit (107) is configured to short-circuit the two electrodes (105, 106) in case a voltage signal from the sensor circuit (103) applied to the electrodes (105, 106) exceeds a predetermined voltage threshold. The invention further relates to a method (300) for operating an analyte sensor.
Absstract of: WO2024173658A2
An infusion system comprising: a device configured to deliver medication to a user through an infusion catheter, wherein the device includes a housing configured to receive the infusion catheter and to maintain the infusion catheter in the user after insertion; and a detachable activation mechanism for deploying the device for delivering medication to the user, wherein the detachable activation mechanism comprises a trigger and a retraction mechanism that includes an introducer needle for introducing the infusion catheter into the user, wherein the detachable activation mechanism is configured to releasably connect to the housing, wherein the detachable activation mechanism is configured to insert the infusion catheter into the user, automatically release the detachable activation mechanism from the housing responsive to activation of the trigger and automatically retract the introducer needle into the needle retraction assembly to shield the needle upon the automatic release of the detachable activation mechanism.
Absstract of: WO2024168793A1
The present application discloses a safety insulin pen needle, comprising: a needle hub, wherein a fixing stud protruding along with an injection needle is arranged on the needle hub, and clamping steps are arranged on the surface of the fixing stud; a protective cap, wherein the injection needle is inserted into the protective cap, a spring is sandwiched between the protective cap and the needle hub so that the protective cap can axially move relative to the needle hub to expose or cover a needle tip of the injection needle, a flange is arranged on the outer wall of the protective cap, a first limiting step and a second limiting step are arranged on the inner wall of the protective cap in an insertion direction of the injection needle, and the inner diameter size of the second limiting step is smaller than that of the first limiting step; a needle cap, assembled and fixed to the needle hub and covering the protective cap, wherein a through hole allowing the protective cap to extend out is formed in the needle cap, and the through hole limits the flange; and a limiting block, located in an inner cavity of the protective cap and sleeved on the injection needle, wherein a clamping jaw fitted to the clamping steps is arranged at a first end of the limiting block, and a second end of the limiting block is fitted to the first limiting step or the second limiting step to stop the protective cap.
Absstract of: US2024282442A1
Medical devices, systems, and methods related thereto a glucose monitoring system having a first display unit in data communication with a skin-mounted assembly, the skin-mounted assembly including an in vivo sensor and a transmitter. The first display unit and a second display unit are in data communication with a data management system. The first display unit comprises memory that grants a first user first access level rights and the second display unit comprises memory that grants a second individual second access level rights.
Absstract of: US2024282426A1
Systems and methods are disclosed that employ several or numerous factors in the determination of a glycemic urgency index (GUI), which may be based on a measured blood glucose level as well as other factors. The other factors may include time derivatives of the glucose level and/or other factors, e.g., user-entered data, data measured by other sensors or received from a network source, or historical data. The GUI is then presented to the user in an interesting way, e.g., via a background color or other inconspicuous notifier, e.g., on a mobile device such as a smart phone. The GUI may also be employed in the triggering of actionable alerts and alarms on an electronic device for the user. The GUI, or another index calculated from combinations of the variables and parameters described, may further be employed to drive a medicament delivery device such as a pump.
Absstract of: US2024281966A1
Machine learning systems and methods are disclosed for prediction of wound healing, such as for diabetic foot ulcers or other wounds, and for assessment implementations such as segmentation of images into wound regions and non-wound regions. Systems for assessing or predicting wound healing can include a light detection element configured to collect light of at least a first wavelength reflected from a tissue region including a wound, and one or more processors configured to generate an image based on a signal from the light detection element having pixels depicting the tissue region, determine reflectance intensity values for at least a subset of the pixels, determine one or more quantitative features of the subset of the plurality of pixels based on the reflectance intensity values, and generate a predicted or assessed healing parameter associated with the wound over a predetermined time interval.
Absstract of: US2024282462A1
Detection of anomalous computing environment behavior using glucose is described. An anomaly detection system receives glucose measurements and event records during a first time period. Missing events that are missing from the event records during the first time period are identified by processing the glucose measurements using an event engine simulator. An anomaly detection model is generated based on the missing events during the first time period. Subsequently, the anomaly detection system receives additional glucose measurements and additional event records during a second time period. Missing events that are missing from the additional event records during the second time period are identified by processing the additional glucose measurements using the event engine simulator. Anomalous behavior is detected if the identified missing events that are missing from the event records during the second time period are outside a predicted range of missing events of the anomaly detection model.
Absstract of: US2024277261A1
Computer system and computer-implemented method for rendering representations of blood gas state parameters of a patient to support a medically trained person in blood gas analysis of the patient's blood, comprising: receiving, from a data source, time series of sampled measurement values obtained from a plurality of blood gas analysis sensors for the following blood gas state parameters of the patient: Glucose, Chloride, Potassium, Calcium, Sodium, and Hemoglobin; mapping each state parameter to a predefined corresponding graphical representation with each graphical representation for a particular state parameter being distinct from all graphical representations of the remaining state parameters; and rendering, in a virtual 3D tunnel shaped scene representing the inside of an artery, animated visualizations of the graphical representations, in accordance with predefined animation rules, such that respective graphical objects move through the inside of the artery and reflect current values of the respective state parameters.
Absstract of: US2024277289A1
An electronic device may include a blood glucose sensor configured to generate a blood glucose value by measuring a blood glucose level of a user, at least one processor, and memory storing instructions that, when executed by the at least one processor individually and/or collectively, cause the electronic device to generate logs for the blood glucose value of the user obtained through the blood glucose sensor, determine a target event based on a target blood glucose value of the user obtained through the blood glucose sensor and the logs, and output a message suggesting a target behavior for the target event.
Absstract of: US2024277917A1
A wall-mounted insulin caddy according to the present invention includes a caddy body having a flat rear surface, an outer front surface, a pair of rounded corners, a top caddy body surface and a bottom caddy body surface, one or more removable adhesive strips coupled to the flat rear surface for mounting the caddy body to a wall and label on the outer front surface for identifying contents of any vials stored within the caddy body. The caddy body has a plurality of cylindrical storage locations, each of the plurality of cylindrical storage locations comprises a cavity within the caddy body accessible from a top caddy body surface for storing a vial, and a drainage hole from within the cylindrical storage locations through a bottom caddy surface. The caddy body reduces external light passing into vials placed within one of the plurality of cylindrical storage locations and each of the plurality of cylindrical storage locations has a chamfered vial slot opening for easier vial installation.
Nº publicación: US2024277976A1 22/08/2024
Applicant:
LIXIAO WANG [US]
NEUROTRONIC INC [US]
Lixiao Wang,
Neurotronic, Inc
Absstract of: US2024277976A1
Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
BOPI
Electronic site
